Tempus AI Option Alert: Jan 16 $80 Calls at the Ask: 400 vs 3062 OI

Tempus AI Option Alert: Jan 16 $80 Calls at the Ask: 400 @ $12.8 vs 3062 OI; Ref=$63.385

Tempus AI Option Alert: Jan 16 $30 Calls Sweep (10) near the Ask: 500 vs 2374 OI

Tempus AI Option Alert: Jan 16 $30 Calls Sweep (10) near the Ask: 500 @ $35.9 vs 2374 OI; Ref=$63.96

Tempus AI (NASDAQ:TEM) Stock

TEMPUS AI INC

Tempus AI

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.

Tempus AI Inc

TEMCO

J.P. Morgan Exchange-Traded Fund Trust JPMorgan Climate Change Solutions ETF

PERSOL HLDG CO LTD ORD by Persol Holdings Co Ltd

Persol Holdings Co Ltd

Tradr 2X Long QBTS Daily ETF Tradr 2X Long TEM Daily ETF

Touchstone ETF Trust Touchstone Sands Capital Emerging Markets ex-China Growth ETF

NexGen Energy Ltd.&nbsp; (TSX:<a href="https://www.benzinga.com/stock/NXE#TSX">NXE</a>) (NYSE:<a href="https://www.benzinga.com/stock/NXE#NYSE">NXE</a>) (ASX: NXG)&nbsp;("NexGen" or the "Company")&nbsp;is pleased to announce that the Saskatchewan Ministry of Environment has granted approval for NexGen's 2025 Site Program (the "Program") at its 100%-owned Rook I Property in the Athabasca Basin, Saskatchewan. The Program includes the establishment of a temporary exploration airstrip, expansion of the exploration accommodation camp facilities by 373 beds and site access road improvements.
The Program will commence in the coming weeks and conclude with camp commissioning in Q1 2026. This program builds on NexGen's disciplined, strategic approach to implementing infrastructure enhancements required to support the Company's exploration programs at PCE and that forecast across NexGen's dominant land package in northwestern Saskatchewan into the future.
The drill results of high-grade basement hosted mineralization discovered at PCE 3.5km east from the Arrow deposit indicate another significant scale zone "Arrow style" of mineralization is materializing and warrant these infrastructure enhancements incorporating best practice safety and environmental principles.
Incorporating NexGen's longstanding approach to economic capacity building, the Program will prioritize Local Priority Area participation, generating new employment and contracting opportunities for Indigenous and community members, reflecting NexGen's industry leading and genuine approach to local communities.

Government

News

Regulations

Nuveen Arizona Dividend Advantage Municipal Funds 3

NexGen Gets Green Light for Major Site Expansion in Saskatchewan to Support New Uranium Discovery

Airbus SE (OTC:<a class="ticker" href="https://www.benzinga.com/stock/EADSF#OTC">EADSF</a>) CEO Christian Scherer says the aircraft manufacturer can reach its 2025 delivery target despite delays due to supply chain issues.
What Happened: The company, which is targeting 820 aircraft deliveries in 2025, is "cautiously hopeful" despite over 40 aircraft frames waiting to be fitted with engines, Reuters reported on Thursday.
"We haven&#8217;t changed our (delivery) guidance. I caution you not to extrapolate too much from monthly numbers. There is a gradual increase in output of engines that we get from CFM. The reason we have not changed our outlook for the year is because we believe that between now and the end of the year we will get the engines,&#8221; Scherer said.
The aircraft manufacturer sources its engines from CFM, which also supplies the engines that power Boeing Co.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) 737 Max Aircraft.
Scherer says Airbus can meet its production target of 75 units of single-isle aircraft like the Airbus A320 by 2027. "We are just cruising past 60 (a month). We are trending in the right direction into the 60s," the report said.
Why It Matters: The news comes in as the global aircraft industry is dealing with <a href="https://www.benzinga.com/25/02/43865891/elon-musks-involvement-key-to-solving-boeings-air-force-one-delivery-crisis-report">supply chain constraints</a>. Recently, Boeing <a href="https://www.benzinga.com/tech/25/04/44896693/boeing-secures-new-stocks-of-crucial-nuts-and-bolts-used-in-737-max-production-amid-chinas-import-ban-report">replenished its stockpile</a> of crucial nuts used in the production of its best-selling 737 Max aircraft.
Boeing has endured a tough spell in recent years over quality control and safety issues with its aircraft. Most recently, A London-bound <a href="https://www.benzinga.com/markets/equities/25/06/45899174/boeing-dreamliner-carrying-over-200-passengers-crashes-shortly-after-takeoff-near-indias-ahmedabad-ba-stock-falls-over-5-in-thursday-pre-market">Boeing 787 Dreamliner</a> aircraft operated by Air India crashed moments after it took off from Ahmedabad in India&#8217;s Gujarat state on Thursday. The flight was said to be carrying over 240 people onboard.
The FAA, or Federal Aviation Administration, also recently proposed a flightworthiness report for the company after <a href="https://www.benzinga.com/25/04/44811150/faulty-bathroom-latches-could-cost-boeing-34-million-following-faa-directive">faulty bathroom latches</a> resulted in a passenger being stuck inside the lavatory of a Boeing aircraft during a flight.
Airbus recently <a href="https://www.benzinga.com/25/04/45035715/airbus-finalizes-deal-with-spirit-to-take-over-assets-paving-way-for-boeing-acquisition">finalized a deal</a> with Spirit Aerosystems Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPR#NYSE">SPR</a>) to acquire assets of the company, including a facility in Kinston, North Carolina, as well as another facility in France. Spirit was recently acquired by Boeing.
Check out more of Benzinga's Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/06/45831511/boeing-737-max-deliveries-to-china-restart-after-month-long-pause-amid-trade-tensions-with-us-over-trumps-tariffs">Boeing 737 MAX Deliveries To China Restart After Month-Long Pause Amid Trade Tensions With US Over Trump&#8217;s Tariffs</a></li>
</ul>
Photo courtesy: Manuel Esteban / Shutterstock.com

Equities

EADSF

Boeing Rival Airbus Says It Can Hit 2025 Delivery Goals Amid Delays Caused By Supply Chain Constraints

Needham analyst Mike Cikos maintains Datadog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) with a Buy and raises the price target from $130 to $140.

Price Target

Analyst Ratings

DDOG

Needham Maintains Buy on Datadog, Raises Price Target to $140

ADC Therapeutics SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADCT#NYSE">ADCT</a>), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced updated data&nbsp;from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA&#xAE;&nbsp;in combination with the bispecific antibody glofitamab (COLUMVI&#xAE;) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) to be presented at the European Hematology Association 2025 Congress (EHA2025) in Milan, Italy. The Company will host a conference call and webcast featuring LOTIS-7 trial principal investigator and EHA presenting author, Juan Alderuccio, MD, Clinical Site Disease Group Leader, Lymphoma Section, at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine today at 8:00 a.m. ET to discuss the results. To access the conference call, please register <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4447834-1&amp;h=1413992372&amp;u=https%3A%2F%2Fapp.webinar.net%2FRp8ZqrVqKdQ&amp;a=here">here</a>.
&nbsp;
"The data seen in this study with the combination of ZYNLONTA and glofitamab has shown a manageable safety profile along with strong efficacy data from patients with relapsed or refractory DLBCL, with complete responses observed regardless of prior therapy, including CAR-T," said Mohamed Zaki, MD, PhD, Chief Medical Officer of ADC Therapeutics. "The combination of these two anti-cancer agents holds significant promise for advancing the treatment landscape and addressing unmet need in patients with these hard-to-treat lymphomas."
The presentation highlights updated data as of April 14, 2025, in which r/r LBCL patients received dose levels of 120 µg/kg or 150 µg/kg of ZYNLONTA plus the bispecific antibody glofitamab, with 41 patients evaluable for safety and 30 patients evaluable for efficacy.
Key highlights of the LOTIS-7 data presentation are as follows:
<ul>
<li>Best overall response data among the 30 efficacy evaluable patients shows overall response rate (ORR) of 93.3% (28/30 pts) as assessed by Lugano Criteria</li>
<li>Complete response (CR) rate of 86.7% (26/30 pts)
<ul>
<li>Of these, 25/26 patients achieving CR remain in CR as of the data cut-off
<ul>
<li>Median time to CR in 120 µg/kg = 80 days</li>
<li>Median time to CR in 150 µg/kg = 42 days</li>
</ul>
</li>
</ul>
</li>
<li>12 patients converted from stable disease (SD) or partial response (PR) to CR over time (1 and 11 pts respectively)</li>
<li>Of the 6 patients previously treated with CAR-T and undergoing response assessment, 5 achieved a CR</li>
<li>Among the 41 safety&nbsp;evaluable patients, the combination was generally well tolerated with a manageable safety profile and no DLTs across dose levels
<ul>
<li>Grade 3 or higher treatment emergent adverse events (TEAEs) observed in &gt; 5% of patients included neutropenia (24.4%), anemia (9.8%), AST increased (7.3%), GGT increased (7.3%), and thrombocytopenia (7.3%)</li>
<li>In the 150 µg/kg dose, cytokine release syndrome (CRS) (23.8%), all of which were Grade 1, and immune effector cell-associated neurotoxicity syndrome (ICANS) (4.8%), with one case of Grade 2, were observed</li>
<li>In the 120 µg/kg dose, CRS all grades (55%), all of which were Grade 1/2 except one case of Grade 3, and ICANS (10%), with one case of Grade 1 and one case of Grade 2, were observed</li>
<li>TEAEs leading to discontinuation included 3 each for&nbsp;ZYNLONTA and glofitamab</li>
<li>There were no Grade 5 TEAEs observed</li>
</ul>
</li>
</ul>

ADCT

ADC Therapeutics Reports 93% Response Rate in Lymphoma Drug Trial, Including CAR-T Resistant Patients

Teleflex Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>), a leading global provider of medical technologies, today announced findings from a new multinational study reporting efficacy of Arrow&#x2122; Chlorhexidine-Impregnated Central Venous Catheters (CVCs). This prospective cohort study included more than 6,670 patients from 12 Intensive care units in eight hospitals across India, Malaysia, Papua New Guinea, Colombia, Egypt and Turkey.
Key highlights include:
<ul>
<li>The pre-specified CVC subgroup analysis evaluated the impact of Chlorhexidine-impregnated CVCs on CLABSI rates using CLABSI rates per 1,000 CL (central-line)-days.</li>
<li>70.5% reduction in the incidence of CLABSI in patients with Arrowg+ard Blue&#x2122; and Arrowg+ard Blue Plus&#x2122; CVCs vs. plain (non-impregnated) catheters.</li>
<li>Lower incidence of infection-causing pathogens with Chlorhexidine-impregnated CVCs, including gram-negative and gram-positive bacteria and fungi.</li>
<li>Insertion training and the use of maximal barrier precautions were similar across both groups, eliminating technique variability as a confounding factor.</li>
<li>Use of an unprotected CVC may be an independent risk factor for CLABSI when compared to patients with Chlorhexidine-impregnated CVCs. &nbsp;</li>
</ul>
The study's CVC analysis demonstrated a statistically significant reduction in CLABSIs of 70.5% in patients receiving the impregnated antimicrobial catheters. These patients had longer average length of ICU stay and device utilization ratios, indicating frequent and extended use. Despite this, infection remained significantly lower, underscoring the potential benefit of the antimicrobial technology even in high-risk patients. Acknowledging potential variations in patients and characteristics across study hospitals and the lack of a metric (e.g., Standard Infection Ratio) to adjust for these factors in the countries in the study, the authors noted that the study data nonetheless provides "significant evidence" regarding impregnated CVCs.

Teleflex Catheters Cut ICU Infection Risk by Over 70%, Study Finds in 6-Country Trial

Needham analyst Laura Martin reiterates DoubleVerify Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DV#NYSE">DV</a>) with a Buy and maintains $18 price target.

Reiteration

Needham Reiterates Buy on DoubleVerify Holdings, Maintains $18 Price Target

Chimera Investment Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIM#NYSE">CIM</a>) ("Chimera") today announced that on June 11, 2025, it entered into a definitive agreement to acquire HomeXpress Mortgage Corp. ("HomeXpress") from certain affiliates of Seer Capital Management's credit fund business ("Seer") and certain management sellers (together with Seer, the "Sellers"). HomeXpress is a leading originator of consumer non-QM, investor business purpose, and other non-Agency mortgage loan products, as well as an originator of Agency mortgage loans with a nationwide presence across 46 states and D.C.
"We are thrilled to welcome HomeXpress to the Chimera team," said Phillip J. Kardis II, President and Chief Executive Officer of Chimera. "We believe that the transaction is the natural next step in the transformation of Chimera. Bringing together Chimera's strong history of loan securitization, structured finance, and third-party loan management and advisory services with HomeXpress' loan origination platform is expected to create a powerful combination and enhance our enterprise value. HomeXpress has an excellent management team with experienced origination professionals that have a long history of serving broker and correspondent partners across the U.S. We expect this acquisition to be accretive to Chimera's earnings in 2026."
Strategic Rationale and Benefits to Chimera Shareholders
<ul>
<li>Highly Synergistic with Chimera's Platform
<ul>
<li>The combination of HomeXpress' non-QM origination platform and our loan management and advisory services is expected to create a tremendous cross-selling opportunity.</li>
<li>Provides opportunity for Chimera to acquire and securitize loans on a direct basis.</li>
<li>Supports Chimera's efforts to build an MSR portfolio.</li>
<li>Presents an opportunity to create enterprise value at the platform level.</li>
</ul>
</li>
<li>Attractive and Diverse Returns
<ul>
<li>Existing net operating losses at Chimera are expected to cover a substantial amount of the acquisition premium.</li>
<li>Continues the diversification of Chimera's income streams to include origination fees and gain on sale income.</li>
</ul>
</li>
</ul>
HomeXpress Highlights
<ul>
<li>A leading national non-QM originator</li>
<li>Approximately 300 employees and lending in 46 states and D.C.</li>
<li>$2.5 billion UPB of funded origination volume in 2024</li>
<li>$3.5 billion UPB of estimated origination volume for the full year 2025, with $1.2 billion UPB of year-to-date funded origination volume through May 2025</li>
<li>Made first loan in 2016 and has been profitable every year since</li>
<li>2024 pre-tax net income of $47 million</li>
<li>$115 million of GAAP Total Equity as of March 31, 2025</li>
<li>Partner of choice for brokers and correspondent lenders across U.S.</li>
<li>Experienced management team</li>
</ul>
Key Transaction Details
Under the terms of the agreement, Chimera will cause its taxable REIT subsidiary, Chimera Funding TRS, to acquire HomeXpress from the Sellers for a combination of cash and 2,077,151 shares of Chimera common stock. The purchase price will be equal to the adjusted book value of HomeXpress as of the end of the month prior to the closing, plus a premium consisting of $120 million in cash plus 2,077,151 shares of Chimera common stock. HomeXpress will operate as a subsidiary of Chimera and Kyle Walker, the current President and CEO, along with key members of the senior management team will continue to manage HomeXpress. Chimera expects to close the transaction during the fourth quarter of 2025, subject to the satisfaction of customary closing conditions.

Chimera to Acquire HomeXpress for $120M Plus 2.08M Shares to Expand Loan Origination

Xpeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) debuted the new all-electric G7 SUV in China as the country's brutal EV price war shows no signs of relenting.
What Happened: The Chinese automaker received over 10,000 pre-orders for the G7 SUV in under 46 minutes, CnEVPost reported <a href="https://cnevpost.com/2025/06/12/xpeng-g7-10000-pre-orders-46-mins/">on</a> Thursday.
Xpeng says display models of the SUV are available across multiple outlets in China. The SUV would retail for around 235,810 Yuan or slightly under $33,000, pitting it squarely against Tesla Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) cheapest vehicle in China, the Model 3.
Also Read:<a href="https://www.benzinga.com/markets/asia/25/06/45881963/tesla-supplier-catl-hits-milestone-with-1-million-battery-packs-delivered-to-li-auto"> Tesla Supplier CATL Hits Milestone With 1 Million Battery Packs Delivered To Li Auto</a>
The SUV also features Xpeng's Turing AI chip, which is developed in-house by the automaker, marking a shift away from the previously utilized Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) autonomous driving chipsets.
Why It Matters: The G7 debuts in what is a cutthroat market as China's EV price war has put pressure on the country's supply chains, with several automakers, including EV giant BYD Co. Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDF#OTC">BYDDF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>) pledging <a href="https://www.benzinga.com/markets/tech/25/06/45878086/tesla-rivals-byd-xpeng-pledge-faster-supplier-payments-amid-ev-price-war-in-china-report">faster payments to suppliers</a>.
The EV price war was also called out by the Chinese Communist Party's newspaper, <a href="https://www.benzinga.com/news/topics/25/06/45715047/byds-aggressive-pricing-triggers-ev-rat-race-stock-tumbles-authorities-voice-concern">The People's Daily</a>, which equated it to a ‘rat race' and warned of negative effects on the country's supply chain, as well as product quality issues, among other things.
However, the aggressive pricing strategy continues as BYD recently released the <a href="https://www.benzinga.com/markets/tech/25/06/45855643/tesla-rival-byd-launches-15000-seal-06-sedan-as-chinas-ev-price-war-heats-up">Seal 06 EV</a> sedan, which retails for $15,000, undercutting the Tesla Model 3 as well as the G7 SUV's price by almost half.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/45855123/teslas-model-y-tops-china-suv-sales-chart-in-may-with-over-24700-cars-sold">Tesla&#8217;s Model Y Tops China SUV Sales Chart In May With Over 24,700 Cars Sold</a></li>
</ul>
Photo courtesy: THINK A / Shutterstock.com

Tech

BYDDF

BYDDY

NVDA

TSLA

XPEV

Xpeng Receives 10,000 Pre-Orders In Under An Hour For New Tesla Model 3 Rival: Report

Shares of Oracle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) rose sharply in today's pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued upbeat <a href="https://www.benzinga.com/quote/ORCL">outlook commentary</a>.
The company reported fourth-quarter revenue of $15.9 billion, beating analyst estimates of $15.58 billion. The company reported fourth-quarter adjusted earnings of $1.70 per share, beating analyst estimates of $1.64 per share, according to Benzinga Pro.
Oracle shares jumped 7.6% to $189.99 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>Healthcare Triangle, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) surged 141.3% to $0.0222 in pre-market trading after gaining 28% on Wednesday.</li>
<li>Greenlane Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares jumped 78% to $0.0137 in pre-market trading after adding 8% on Wednesday.</li>
<li>Creative Global Technology Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTL#NASDAQ">CGTL</a>) jumped 73.4% to $1.60 in pre-market trading.</li>
<li>Graphjet Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTI#NASDAQ">GTI</a>) gained 26.6% to $0.0814 in pre-market trading. Graphjet Technology, on June 11, submitted appeal to the Nasdaq Requesting hearing before Hearings Panel.</li>
<li>Zhongchao Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCMD#NASDAQ">ZCMD</a>) climbed 24.1% to $1.29 in pre-market trading after dipping 22% on Wednesday.</li>
<li>Houston American Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUSA#NYSE">HUSA</a>) rose 22.2% to $6.65 in pre-market trading after jumping 24% on Wednesday.</li>
<li>Liminatus Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) rose 21.8% to $13.53 in pre-market trading after dipping 50% on Wednesday.</li>
<li>Applied Optoelectronics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAOI#NASDAQ">AAOI</a>) surged 14.7% to $18.70 in pre-market trading after the company announced the first volume shipment of data center transceivers to a hyperscale customer.</li>
<li>Solid Power, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDP#NASDAQ">SLDP</a>) gained 13.4% to $2.12 in pre-market trading after jumping 15% on Wednesday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>Intensity Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>) shares tumbled 47.7% to $0.3020 in pre-market trading after the company announced a proposed public offering.</li>
<li>Helius Medical Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) dipped 42.5% to $0.6397 in pre-market trading. Helius Medical Technologies shares gained 31% on Wednesday after the company announced an authorized claim for payment for the PoNS Device from Aetna Healthcare.</li>
<li>Catheter Precision, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#NASDAQ">VTAK</a>) shares fell 30.2% to $0.4223 in pre-market trading after jumping 165% on Wednesday.</li>
<li>Jupiter Neurosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JUNS#NASDAQ">JUNS</a>) declined 19.6% to $1.60 in pre-market trading after jumping 106% on Wednesday.</li>
<li>Hycroft Mining Holding Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYMC#NASDAQ">HYMC</a>) declined 19.5% to $3.43 in pre-market trading after the company announced a $40 million public offering of units.</li>
<li>Distoken Acquisition Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DIST#NASDAQ">DIST</a>) fell 18.8% to $16.00 in pre-market trading after jumping 64% on Wednesday.</li>
<li>Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) dipped 17% to $31.32 in pre-market trading. Tonix Pharmaceuticals may sell up to $150 million in common stock.</li>
<li>707 Cayman Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JEM#NASDAQ">JEM</a>) declined 17% to $5.76 in pre-market trading after jumping 73% on Wednesday.</li>
<li>GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) fell 12.4% to $24.97 in pre-market trading after the company announced a $1.75 billion proposed private offering of convertible senior notes.</li>
<li>Oxford Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXM#NYSE">OXM</a>) fell 10.1% to $44.99 in pre-market trading. Oxford Industries reported in-line earnings for the first quarter and issued second-quarter earnings guidance below estimates.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45882911/top-2-consumer-stocks-that-may-plunge-in-june">Top 2 Consumer Stocks That May Plunge In June</a> </li>
</ul>
Photo via Shutterstock

AAOI

CGTL

DIST

GNLN

HCTI

HSDT

HUSA

Hycroft Mining Holding Corporation - Class A Common Stock

HYMC

INTS

JUNS

LIMN

ORCL

SLDP

TNXP

VTAK

ZCMD

Why Oracle Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

Large Cap

Dividends

General

Target Declares A Quarterly Dividend Of $1.14 Per Common Share, A 1.8% Increase From The Prior Quarterly Dividend Of $1.12, The Dividend Is Payable September 1 To Shareholders Of Record At The Close Of Business August 13

Stephens &amp; Co. analyst Jim Salera reiterates Papa John's International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PZZA#NASDAQ">PZZA</a>) with a Overweight and maintains $50 price target.

PZZA

Stephens & Co. Reiterates Overweight on Papa John's International, Maintains $50 Price Target

Needham analyst Serge Belanger reiterates NewAmsterdam Pharma Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAMS#NASDAQ">NAMS</a>) with a Buy and maintains $40 price target.

NAMS

Needham Reiterates Buy on NewAmsterdam Pharma Co, Maintains $40 Price Target

<a href="https://www.ft.com/content/094e755d-448d-405e-aa01-f768584c4a16" title="https://www.ft.com/content/094e755d-448d-405e-aa01-f768584c4a16">https://www.ft.com/content/094e755d-448d-405e-aa01-f768584c4a16</a>

Financial Times Reported  Xpeng Claims Its Self-designed Turing Processors Outperform Those Of Nvidia

An Atari 2600 chess cartridge has humiliated OpenAI's vaunted ChatGPT, highlighting the limits that large language models still face outside pure text.
What Happened: Citrix engineer Robert Caruso <a href="https://www.linkedin.com/posts/robert-jr-caruso-23080180_ai-chess-atari2600-activity-7337108175185145856-HSP0/">pitted</a> ChatGPT-4o against Video Chess (1979) through an emulator and watched the bot "get absolutely wrecked on the beginner level," he wrote on LinkedIn.
Caruso said the 90-minute match went downhill immediately: the bot "confused rooks for bishops, missed pawn forks and repeatedly lost track of where pieces were," first blaming Atari's pixel icons and then floundering even after he switched to algebraic notation.
The system begged to restart several times before the 1.19 MHz console sealed the win.
Chess has long served as a yardstick for machine intelligence. IBM's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) Deep Blue dethroned the world champion, then Garry Kasparov, in 1997, but ChatGPT is a language generator and not a search-heavy chess engine, and therefore unlikely to serve that purpose well.
See also: <a href="https://www.benzinga.com/markets/tech/25/06/45899881/apple-study-asks-whether-ai-can-think-for-itself-experts-say-its-limits-are-human-made">Apple Study Asks Whether AI Can Think For Itself: Experts Say Its Limits Are Human-Made</a>
Developers have tried to bridge the gap with plugins such as ChessGPT, yet the model still stumbles at board-state memory and legal-move tracking, as Caruso states.
Why It Matters: The flop arrives as ChatGPT jostles with Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) Google's Gemini, Microsoft's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) Copilot and Anthropic's Claude for everyday users. Alphabet recently expanded new <a href="https://www.benzinga.com/markets/25/05/45537306/google-unveils-total-reimagining-of-search-with-chatbot-style-feature-to-compete-with-openai">Gemini AI additions</a> to its search engine. OpenAI, for its part, rolled out a more "reliable" GPT-o3 Pro model earlier this week, hoping to keep developers loyal.
OpenAI on Monday said its annualized revenue run rate has <a href="https://www.benzinga.com/markets/tech/25/06/45852700/openai-surges-past-10-billion-in-annualized-revenue-amid-record-chatgpt-use-leaves-rivals-like-amazon-backed-anthropic-behind">climbed to $10 billion</a>, nearly doubling the $5.5 billion it posted at the end of 2024. The figure, which excludes Microsoft licensing fees and other one-off deals, reflects recurrent sales driven by ChatGPT's growing base of 500 million weekly active users as of March.
The company is reportedly <a href="https://www.benzinga.com/25/04/44580172/openai-finalizes-historic-40-billion-funding-round-valuing-company-at-300-billion-with-backing-from-softbank-and-microsoft">seeking up to $40 billion</a> in a SoftBank-led funding round that could push its valuation to $300 billion. Rival Anthropic, backed by Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and Alphabet, has crossed a $3 billion run-rate after securing $3.5 billion in capital, giving it a $61.5 billion valuation.
Image via Shutterstock
Read next: <a href="https://www.benzinga.com/markets/tech/25/06/45899475/craig-federighi-says-building-a-chatbot-was-never-the-goal-promises-apple-intelligences-focus-is-to-meet-you-where-you-are">Craig Federighi Says &#8216;Building A Chatbot&#8217; Was Never The Goal, Promises Apple Intelligence&#8217;s Focus Is To &#8216;Meet You Where You Are&#8217;</a>

AMZN

GOOG

GOOGL

MSFT

ChatGPT Kept 'Begging To Restart' Before Being Beaten By 1979 Atari 2600 In A 'Beginner Level' Chess Showdown

<a href="https://www.bloomberg.com/news/articles/2025-06-12/mattel-taps-openai-to-help-it-design-toys-other-products" title="https://www.bloomberg.com/news/articles/2025-06-12/mattel-taps-openai-to-help-it-design-toys-other-products">https://www.bloomberg.com/news/articles/2025-06-12/mattel-taps-openai-to-help-it-design-toys-other-products</a>

Bloomberg Reported Mattel Taps OpenAI To Help It Design Toys, Other Products

A new study from Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) is stirring debate about whether AI models can genuinely reason or simply mimic intelligent behavior. By testing systems like GPT-4 variants and Claude on classic logic puzzles, the research suggests that these tools may stumble when real problem-solving is required.
What Happened: Apple released a study challenging the notion that large language models (LLMs) can logically reason through complex tasks. Ars Technica <a href="https://arstechnica.com/ai/2025/06/new-apple-study-challenges-whether-ai-models-truly-reason-through-problems/">explains</a> that by testing popular models like OpenAI's o1 and o3, Claude 3.7 Sonnet, and DeepSeek-R1 on classic logic puzzles such as Tower of Hanoi and river crossing tasks, the research team discovered that these systems often fail when they encounter unfamiliar challenges that demand systematic thinking.
Even when equipped with established algorithms, the models struggled—highlighting a key gap between performing intelligently and actually thinking logically.
"It is truly embarrassing that LLMs cannot reliably solve Hanoi," said AI researcher Gary Marcus, with co-lead Iman Mirzadeh adding the models' behavior shows "their process is not logical and intelligent."
The study also found that while some models performed better on moderately difficult tasks by implementing step-by-step reasoning, they failed completely as complexity increased, often reducing their reasoning effort instead of expanding it.
This odd drop-off in effort, despite ample computing resources, shows what the researchers call a "counterintuitive scaling limit." Inconsistencies were also seen across a variety of puzzles, suggesting the failures are task-specific rather than purely technical.
See Also: <a href="https://www.benzinga.com/markets/equities/25/06/45888626/nvidia-apple-amazon-microsoft-and-alphabets-insitutional-investors-sold-8-4-billion-shares-in-q1-filings-reveal">Nvidia, Apple, Amazon, Microsoft And Alphabet&#8217;s Insitutional Investors Sold 8.4 Billion Shares In Q1, Filings Reveal</a>
Why It Matters: Some experts are countering Apple's conclusions, arguing that the apparent reasoning failures in AI models may originate from built-in constraints rather than inherent flaws.
Pierre Ferragu, an analyst at&nbsp;New Street Research, said that the paper is riddled with <a href="https://www.benzinga.com/markets/tech/25/06/45830549/pierre-ferragu-takes-apple-to-task-for-dismissing-the-ai-revolution-has-its-head-in-the-sand">"ontological nonsense."</a>
Economist Kevin A. Bryan suggested that these systems are trained to use shortcuts under tight computational budgets. He and others note that internal benchmarks show models perform better when allowed more tokens, but production systems restrict this on purpose to avoid inefficiency, meaning the Apple findings might be discovering limits by design, not nature.
Others, like software engineer Sean Goedecke and AI researcher Simon Willison, question whether logic puzzles are even fair tests for language models. Goedecke described DeepSeek-R1's failure on the Tower of Hanoi as a conscious decision to avoid impractical output, not a lack of ability.
Willison added that the test may simply run into token limits, hinting that the paper is more sensational than conclusive. Even Apple's researchers admit the puzzles represent a narrow slice of reasoning challenges and caution against generalizing their results too widely.
The study comes on the heels of the <a href="https://www.benzinga.com/markets/tech/25/06/45844424/apple-wwdc-2025-ios-26-announced-with-liquid-glass-design-new-apple-intelligence-features-and-more">Worldwide Developers Conference (WWDC)</a>, where Apple made a range of new announcements about its products. Experts noted the <a href="https://www.benzinga.com/markets/tech/25/06/45851232/apples-lack-of-new-ai-features-at-wwdc-is-startling-expert-says">absence of any new AI features</a> and expressed disappointment, <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45863934/apple-stock-disappoints-after-wwdc-analyst-says-this-price-is-better-entry-level-for-investors">downgrading the company's stock.</a> Shares fell after the event, with many raising questions about Apple's <a href="https://www.benzinga.com/trading-ideas/movers/25/06/45892008/apples-ai-future-in-question-stock-falls-after-wwdc-2025-event">AI future. </a> 
Price Action: Apple stock is currently trading at $198.76, down -0.01% pre-market.
Benzinga Edge Rankings show that Momentum stands at 29.72, Value at 9.02, Growth at 32.90, and Quality leads the group with a score of 76.94. For more details, click <a href="https://www.benzinga.com/edge/">here.</a>
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/edge/"><img loading="lazy" decoding="async" width="1024" height="201" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12041222/image-180-1024x201.png" alt="" class="wp-image-947232" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12041222/image-180-1024x201.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12041222/image-180-300x59.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12041222/image-180-768x151.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12041222/image-180.png 1170w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/45852236/steve-jobs-would-have-fired-everyone-apples-liquid-glass-in-ios-26-gets-roasted-online-dan-ives-calls-wwdc-2025-a-yawner">Steve Jobs Would &#8216;Have Fired Everyone&#8217;: Apple&#8217;s Liquid Glass In iOS 26 Gets Roasted Online — Dan Ives Calls WWDC 2025 A &#8216;Yawner&#8217;</a></li>
</ul>
Photo courtesy: jamesteohart / Shutterstock.com

AAPL

Apple Study Asks Whether AI Can Think For Itself: Experts Say Its Limits Are Human-Made

Cigna Healthcare, the health benefits division of The Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), is introducing a series of new digital features to improve the customer experience during common health insurance interactions, such as checking benefits coverage, estimating costs and finding care. These enhancements are designed to provide a reliably simple experience for everyday needs and are an important step in delivering on the company's <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4447778-1&amp;h=1231182111&amp;u=https%3A%2F%2Fnewsroom.thecignagroup.com%2F2025-commitments-lets-make-it-better&amp;a=commitment">commitment</a>&nbsp;to make health care easier for customers.
&nbsp;
"We're committed to making our customers' experiences simpler, seamless and more reliable," said Heather Dlugolenski, chief strategy officer, Cigna Healthcare. "That's why we're creating smarter, more connected digital experiences that anticipate our customers' needs while bringing clarity and compassion to everyday moments."
The new digital features, which were developed with rigorous research and testing within a comprehensive artificial intelligence (AI) governance framework,&nbsp;are being made available in a phased rollout through Cigna Healthcare's myCigna member portal. They include:
<ul>
<li>AI-Powered Virtual Assistant: More than a chatbot, this industry-first generative AI tool provides clear, conversational and personalized answers to common questions about benefits coverage, claims and care options. If additional assistance is needed, the virtual assistant seamlessly connects customers to a customer service advocate. Early results show that 2 out of 3 customers who had access to the virtual assistant used it proactively, and more than 4 out of 5 found it helpful.&nbsp;</li>
<li>Personalized Provider Matching: This proprietary matching tool gives customers a tailored list of in-network providers and care delivery methods based on their specific health care needs and preferences. The tool will be integrated soon with the AI Virtual Assistant to help customers quickly find relevant care.</li>
<li>Real-Time Cost Tracking:&nbsp;This redesigned tool provides a simple breakdown of deductibles, out-of-pocket expenses, and integrated bill payments, helping customers track their costs in real time and estimate costs with providers and specialists before engaging.</li>
<li>Smart Claim Submission:&nbsp;This user-friendly feature enables customers to upload bills they receive from physicians and other providers, such as chiropractors or therapists. The tool reads the bill, auto-fills claim details for easy submission, and provides digital updates using plain language on claim statuses and decisions.</li>
<li>Plan Selection Support:&nbsp;Customers who get their health insurance through their employer can compare prices, search for providers, and estimate their potential health care costs when selecting their benefits plan. This helps customers make more informed plan decisions during the open enrollment period.&nbsp;</li>
<li>Early Access to&nbsp;myCigna for New Customers: Customers new to Cigna Healthcare and those with changes to their benefits plans can sign into the myCigna member portal before their plan effective date so they can better plan their health care needs in advance and add their digital ID card to their Apple or Google wallets or provider portals for less paperwork.</li>
</ul>

Cigna Adds AI Tools to Help Customers Track Costs, Find Doctors, and Manage Health Plans

Constellium SE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSTM#NYSE">CSTM</a>), a global leader in aluminum solutions and recycling, and TARMAC Aerosave, a pioneer in aircraft &amp; engine storage, maintenance, and eco-responsible dismantling, are proud to jointly announce a major milestone in sustainable aerospace innovation: the successful recycling and remelting of aluminum from end-of-life aircraft into new, high-performance material suitable for future aerospace applications.
This milestone highlights the potential of aluminum to support circular economy goals in aerospace, without compromising material performance. Following months of collaborative research and development, supported in particular by Airbus and ValoER, Constellium has successfully remelted aluminum recovered by TARMAC Aerosave from retired commercial aircraft, producing material that meets the stringent performance requirements for new aircraft manufacturing. The next step will be to scale up this process for industrial application and to extend it to any aluminum alloy used in metallic aircraft, further demonstrating the full recyclability of end-of-life metallic airframes.

CSTM

Constellium and TARMAC Recycle Aluminum From Retired Aircraft for Future Aerospace Use

<a href="https://www.cnbc.com/2025/06/12/nvidia-ceo-if-us-wont-participate-in-china-huawei-has-china-covered.html" title="https://www.cnbc.com/2025/06/12/nvidia-ceo-if-us-wont-participate-in-china-huawei-has-china-covered.html">https://www.cnbc.com/2025/06/12/nvidia-ceo-if-us-wont-participate-in-china-huawei-has-china-covered.html</a>

Nvidia CEO Jensen Huang, In CNBC Interview Earlier,  Said U.S. Technology Is A Generation Ahead Of China's; Said Huawei Will Take Advantage Of Its Position In China If The U.S. Continues To Restrict Access To The Market

Press Releases

Tempus Introduces Fuses, A Program Designed to Transform Therapeutic Research and Build the Largest Diagnostic Platform Using its Novel Foundation Model

Introducing Tempus One in the EHR with Integrated Guidelines

Short Sellers

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tempus AI, Inc. - TEM

Tempus Introduces xM, An Assay to Monitor Immunotherapy Response for Patients with Advanced Cancers

Legal

TEMPUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Tempus AI, Inc. on Behalf of Tempus Stockholders and Encourages Investors to Contact the Firm

Rosen Law Firm Encourages Tempus AI, Inc. Investors to Inquire About Securities Class Action Investigation - TEM

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims  On Behalf of Investors of Tempus AI, Inc. - TEM

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solutions

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Date	Put/Call	Strike Price	Exp Date	DTE	Trade Vol	Day Vol	Vol / OI	OI	Trade Type	Sentiment
01:57 PMMay 20, 2025	CALL	$80.00	Jan 16, 2026	217	440	400	14	3062	TRADE	BULLISH
09:42 AMMay 15, 2025	CALL	$30.00	Jan 16, 2026	217	500	500	21	2374	SWEEP	BULLISH

Comments

Tempus AI

Unusual Options Activity for

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL